A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

NCT00100152 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphoblastic, Acute, T-cell
Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: MK0752, (Notch Inhibitor)

Sponsor

Merck Sharp & Dohme LLC